Skip to main content
Equibles
NXGL logo

NXGL · Nexgel, Inc.

Track NXGL — free

Use NXGL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.35 -0.01 (-2.96%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had an unrestricted cash balance of $0.5 million. For the six months ended June 30, 2026, the Company incurred a net loss of $4.5 million and had a net usage of cash in operating activities of $2,701 thousand. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 17, 2026
Market Cap
$3.49M
Shares
9.75M

NXGL metrics

62 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.35
Market cap
$3.49M

Price action

19 metrics
Price change (1W)
+0.6%
Price change (30D)
-15.4%
Price change (3M)
-38.4%
Price change (6M)
-66.9%
Price change (YTD)
-77.8%
Price change (1Y)
-85.4%
Trailing year
Price change (5Y)
—
52-week high
$2.78
52-week low
$0.33
Change from 52-week high
-87.1%
Change from 52-week low
+8.5%
Annualized volatility
108.7%
Beta
0.5
RSI (14D)
44.1
Price vs SMA 50
-19.3%
Price vs SMA 200
-61.4%
Avg volume (3M)
746,342
Relative volume
0.2
Average dollar volume
$325,709

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
9.75M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 345.8%
P / book
0.7
reciprocal yield 141.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-178.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.3×
reciprocal yield 77.4%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 77.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-12

Profitability

9 metrics
Gross margin
35.1%
Operating margin
-44.8%
Trailing 12 months
Net margin
-51.5%
Gross profit (TTM)
$4.23M
Operating profit (TTM)
−$5.40M
Net income (TTM)
−$6.22M
Trailing 12 months
Diluted EPS (TTM)
$-0.71
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
+27.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$12.07M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+17.8%
Year over year · more shares
Revenue CAGR (3Y)
+77.3%
Revenue CAGR (5Y)
+76.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-125.7%
Return on assets
-23.5%
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
−$4.25M
Free cash flow (TTM)
—
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.71M
Total assets
$26.45M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.21M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
$9.61M
Stock compensation (TTM)
$623,000
R&D / revenue
—
Stock compensation / revenue
5.2%

Ownership (13F)

3 metrics
13F filers
24
13F filer change QoQ
+2
Institutional ownership
15.0%

Short interest

3 metrics
Short interest
2.8%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$10,001
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1468929 CUSIP 65344E107 13F (30d) 22 filings 22 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)